NCT05199584View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 24, 2022

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Solid Tumors With PTCH1 Loss-of-function Mutations
Interventions
DRUG

ENV-101 (taladegib)

tablets dosed once-daily

Trial Locations (16)

10065

Research Site, New York

15232

Research Site, Pittsburgh

22408

Research Site, Fredericksburg

24501

Research Site, Lynchburg

27710

Research Site, Durham

33609

Research Site, Tampa

37203

Research Site, Nashville

43210

Research Site, Columbus

45229

Research Site, Cincinnati

53792

Research Site, Madison

60099

Research Site, Zion

70433

Research Site, Covington

77030

Research Site, Houston

89102

Research Site, Las Vegas

90095

Research Site, Los Angeles

95403

Research Site, Santa Rosa

Sponsors
All Listed Sponsors
lead

Endeavor Biomedicines, Inc.

INDUSTRY

NCT05199584 - A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | Biotech Hunter | Biotech Hunter